Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Sale
The global Allergy Immunotherapy market is expected to grow at a CAGR of 10.1% during the period 2022-2027. North America, Europe and Asia Pacific are likely to be key markets.
In the USA, over 7.5% of the people eighteen years of age or above experience allergic rhinitis or hay fever. A significant percentage of children also suffers from hay fever. Allergic rhinitis affects ten to thirty percent of the population across the globe. Further, over five percent of children across the world experience some kind of food allergy. Globally, increase in prevalence of allergic diseases has continued in the industrialized world for over fifty years. Such prevalence of allergic conditions is expected to drive the global allergy immunotherapy market. Allergies can have a significant affect on health and quality of life. Allergen immunotherapy can provide long-lasting therapeutic relief to people suffering from environmental allergies. Allergen immunotherapy (also called allergy shots) refers to a type of long-term treatment that reduces symptoms for individuals experiencing allergic rhinitis, allergic asthma, conjunctivitis (eye allergy) or stinging insect allergy. Allergy shots reduce sensitivity to allergens and usually offer lasting relief from allergy symptoms even after the treatment is stopped, making it an economical and beneficial treatment approach for several people. Immunotherapy is a preventive treatment for allergic reactions to substances like grass pollens, house dust mites and bee venom; it also decreases inflammation that characterizes rhinitis and asthma.
Adults as well as children may receive allergy shots, however, the treatment is not usually suggested for children below age five. When considering allergen immunotherapy for an older adult, medical conditions including cardiac disease must be taken into consideration. Important considerations include: duration of allergy season and severity of symptoms; how well medications and environmental controls are helping allergy symptoms; the patient’s desire to avoid long-term medication use; time available for treatment; cost. Food allergies are not treated through allergy shots.
Allergy shots act like a vaccine; the body responds to injected amounts of a specific allergen, administered in gradually increasing doses, by developing immunity or tolerance to the allergen. The gradual increases of the allergen enable the immune system to become less sensitive to the substance, possibly by causing production of a “blocking” antibody which decreases the symptoms of allergy when the substance is encountered in the future. In the build-up phase, injections are administered with increasing amounts of the allergens one to two times per week; the phase may last three to six months. The maintenance phase commences once the effective dose is reached; the effective dose depends on allergen sensitivity levels and the person’s response to the build-up phase. During the maintenance phase, the duration of time between shots might become longer (two to four weeks).
Allergen immunotherapy has been shown to reduce symptoms of several allergies; it may also prevent the development of new allergies. In children, it could prevent the development of allergic disease from allergic rhinitis to asthma. The relief provided by allergen immunotherapy is expected to boost the global allergy immunotherapy market.
Indications for allergen immunotherapy include moderate-to-severe allergic rhinitis; allergic asthma; allergic conjunctivitis; allergic rhino-conjunctivitis; atopic dermatitis; immune-mediated and IgE-mediated food allergy; insect allergy that causes significant local reaction and anaphylaxis.
In 2020, it was reported that researchers from the University of Tsukuba had developed a novel system that enabled the mass production of the major birch pollen allergen Bet v 1 in plant leaves in just a few days. A study published in Frontiers in Plant Science showed that their system not only produced large amounts of Bet v 1, but the purified protein was also highly reactive towards the IgE antibodies in sera from individuals with birch pollen allergy. Such developments, along with several others in the domain, are expected to boost the global allergy immunotherapy market.
By allergy, the market is segmented into:
By treatment, the market is divided into:
By distribution channel, the market is classified into:
By region, the market is segmented into:
The report presents a detailed analysis of the following key players in the global Allergy Immunotherapy market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2021 |
Historical Period | 2017-2021 |
Forecast Period | 2022-2027 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Allergy |
|
Breakup by Treatment |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Allergy Immunotherapy Market Analysis
8.1 Key Industry Highlights
8.2 Global Allergy Immunotherapy Historical Market (2017-2021)
8.3 Global Allergy Immunotherapy Market Forecast (2022-2027)
8.4 Global Allergy Immunotherapy Market by Allergy
8.4.1 Allergic Asthma
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Cat Allergy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Allergic Rhinitis
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Peanut Allergy
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.4.5 Others
8.5 Global Allergy Immunotherapy Market by Treatment
8.5.1 Sublingual Immunotherapy
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Subcutaneous Immunotherapy (SCIT)
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Specific Immunotherapy (SIT)
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.6 Global Allergy Immunotherapy Market by Distribution Channel
8.6.1 Retail Pharmacy
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Hospital Pharmacy
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Online Pharmacy
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.7 Global Allergy Immunotherapy Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 ASIT Biotech
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Circassia Group PLC
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Adamis Pharmaceuticals Corporation
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Merck KGaA
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Stallergenes Greer Ltd
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Allergy Therapeutics PLC
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Allergy Immunotherapy Market: Key Industry Highlights, 2017 and 2021
2. Global Allergy Immunotherapy Historical Market: Breakup by Allergy (USD Million), 2017-2021
3. Global Allergy Immunotherapy Market Forecast: Breakup by Allergy (USD Million), 2022-2027
4. Global Allergy Immunotherapy Historical Market: Breakup by Treatment (USD Million), 2017-2021
5. Global Allergy Immunotherapy Market Forecast: Breakup by Treatment (USD Million), 2022-2027
6. Global Allergy Immunotherapy Historical Market: Breakup by Distribution Channel (USD Million), 2017-2021
7. Global Allergy Immunotherapy Market Forecast: Breakup by Distribution Channel (USD Million), 2022-2027
8. Global Allergy Immunotherapy Historical Market: Breakup by Region (USD Million), 2017-2021
9. Global Allergy Immunotherapy Market Forecast: Breakup by Region (USD Million), 2022-2027
10. North America Allergy Immunotherapy Historical Market: Breakup by Country (USD Million), 2017-2021
11. North America Allergy Immunotherapy Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Europe Allergy Immunotherapy Historical Market: Breakup by Country (USD Million), 2017-2021
13. Europe Allergy Immunotherapy Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Asia Pacific Allergy Immunotherapy Historical Market: Breakup by Country (USD Million), 2017-2021
15. Asia Pacific Allergy Immunotherapy Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Latin America Allergy Immunotherapy Historical Market: Breakup by Country (USD Million), 2017-2021
17. Latin America Allergy Immunotherapy Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Middle East and Africa Allergy Immunotherapy Historical Market: Breakup by Country (USD Million), 2017-2021
19. Middle East and Africa Allergy Immunotherapy Market Forecast: Breakup by Country (USD Million), 2022-2027
20. Global Allergy Immunotherapy Market Structure
The market is projected to grow at a CAGR of 10.1% between 2022 and 2027.
The major drivers of the market include the climate change, standardisation of dosage, strong pipeline of immunotherapy products, and increased consumption of alcohol.
The rising prevalence of allergic disorders and increasing air pollution, both indoors and outdoors, are the key industry trends propelling the market's growth.
For some allergies, success rates have been shown to be as high as 80-90%. It is a lengthy procedure; if therapy is effective, it should be continued for three to five years after considerable improvement is seen.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major allergies studied in the market are allergic asthma, cat allergy, allergic rhinitis, and peanut allergy, among others.
Based on treatment, the market is classified into sublingual immunotherapy, subcutaneous immunotherapy (SCIT), and specific immunotherapy (SIT).
The several distribution channels of the market are retail pharmacy, hospital pharmacy, and online pharmacy.
Treatment with maintenance immunotherapy typically lasts for about 3 to 5 years. The length of allergen immunotherapy varies from person to person, since some people get long-lasting remission of their allergy symptoms, while others may experience relapse after stopping immunotherapy.
The major players in the industry are ASIT Biotech, Circassia Group PLC, Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer Ltd, and Allergy Therapeutics PLC, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.